Grants for City or township governments - Federal

The purpose of this Notice of Funding Opportunity Announcement (NOFO) is to solicit applications for the Coordinating Center (CC) of the ML/AI Tools to Advance Genomic Translational Research (MAGen) Consortium. In collaboration with the MAGen Sites funded by the companion NOFO (RFA-HG-24-004) the CC will explore the feasibility of developing Machine Learning (ML) and Artificial Intelligence (AI) tools that can enhance the accuracy and precision of predicting how individuals with pathogenic genetic variants manifest disease. The CC will be responsible for implementing approaches to bring diverse teams together to enable synergistic and collaborative team science across the Consortium. Specifically, the CC will be responsible for technical, scientific, and administrative coordination activities to support the Consortium research activities including development of consortium wide plans, coordinated ELSI-informed ML/AI tool development and cross validation, and dissemination of the developed resources.

Substance use needs to be better incorporated into interventions for the engagement and retention of sexual minority persons in prevention and care with attention to emergent interventions such as long-acting PrEP. Social determinants of health associated with HIV and problematic substance use such as homelessness and criminal justice involvement also demonstrate disproportionate impact among sexual and gender minorities and need attention. Changing self-definition of sexual minority status has implications for outreach and provider stigma and needs to be better integrated into interventions. This initiative will address these gap areas and support epidemiologic, intervention, and implementation research that incorporates attention to HIV as a syndemic including comorbidities such as STIs, HCV, and psychiatric disorder.

This funding opportunity supports researchers in analyzing and integrating existing data to better understand cancer risks and outcomes, ultimately advancing cancer research and treatment strategies.

This funding opportunity provides financial support to water and power authorities, as well as nonprofit conservation organizations in the western U.S., to implement projects that enhance water efficiency, promote renewable energy, and improve sustainability in response to water scarcity and climate challenges.

The United States Department of the Interior (Department), Bureau of Reclamations (Reclamation) Desalination and Water Purification Research Program (DWPR) works with Reclamation researchers and partners to develop innovative, cost-effective, and technologically efficient ways to desalinate and treat water. DWPR funding plays a critical role in iterating an idea from the lab to a real-world demonstration, yielding products that serve the water treatment community and attract commercialization interest. Reclamation is interested in research where the benefits are widespread but where private-sector entities are not able to make the full investment and assume all the risks. Reclamation is also interested in research that has a national significancewhere the issues are of large-scale concern and the benefits accrue to a large sector of the public. The goal of the DWPR program is to address the need to reduce the costs, energy requirements, and environmental impacts of treating impaired and unusable water. The program also aligns with Executive Order 14008, Tackling the Climate Crisis at Home and Abroad, by investing in development and application of advanced water treatment technologies that expand access to otherwise unusable water resources, thereby increasing water supply flexibility under the risks of long-term climate change and shorter-term drought. For further information on the DWPR Program, see www.usbr.gov/research/dwpr.

This grant provides funding for a Data Coordinating Center to support research projects focused on preventing stillbirth, emphasizing collaboration and equity in addressing disparities in vulnerable populations.

The "Research on Autism Spectrum Disorders" grant aims to fund projects that explore the causes, prevalence, diagnosis, and best service delivery methods for Autism Spectrum Disorders, with a focus on small, well-defined projects that can be completed within two years using limited resources.

The National Institutes of Health (NIH) hereby notify recipient organizations holding specific types of NIH grants, listed in the full Funding Opportunity Announcement (FOA), that applications for change of recipient organization may be submitted to this FOA. This assumes such a change is programmatically permitted for the particular grant. Applications for change of recipient organization are considered prior approval requests (as described in Section 8.1.2.7 of the NIH Grants Policy Statement) and will be routed for consideration directly to the Grants Management Specialist named in the current award. Although requests for change of recipient organization may be submitted through this FOA, there is no guarantee that an award will be transferred to the new organization. All applicants are encouraged to discuss potential requests with the awarding IC before submission.

The purpose of this Notice of Funding Opportunity (NOFO) is to support the development of clinical research platforms that will enable future clinical trials to determine whether combinations of HIV cure strategies can be effective when optimally tailored to the participants. The ultimate goal is for the results of such proof-of-concept clinical studies to inform the development and prioritization of more broad-based curative strategies that will be effective in all people living with HIV. This NOFO will support multidisciplinary teams to conduct coordinated basic and pre-clinical research to profile participants intact, rebound-competent HIV reservoirs and immunologic backgrounds and use that information to develop and test combinations of HIV curative approaches that are specifically tailored to those participants.

Modified release (MR) oral drug products are considered to have a high risk for alcohol dose dumping (ADD) because they contain large quantities of drug(s), designed to release over a prolonged period of time. Accidental exposure of these products to alcohol can result in the relatively rapid release of large quantities of drug with severe side effects, including death. To mitigate this risk, the FDA recommends conducting an in vitro alcohol dose dumping assessment in 0%, 5%, 20%, and 40% alcoholic dissolution media for all prospective generic versions of MR oral drug products. To date, ADD assessments have not been harmonized globally. For instance, the U.S. FDA recommends testing up to 40% alcoholic media while the European Medicines Agency recommends testing up to 20% alcoholic media. This type of difference can present a challenge for formulators designing products for multiple markets, as historical data has shown release from MR oral products do not always follow a linear response (either increasing or decreasing) to increasing alcohol concentrations. In addition, interpretation of an ADD assessment may be limited by the inability of the test to predict in vivo behavior. The purpose of this research is to develop tools that 1) facilitate the development of MR generic drug products that have a low potential for ADD, 2) support regulatory decision making during the assessment of such products, and 3) provide evidence that enables FDA to develop more specific recommendations for efficiently demonstrating a low or comparative potential of alcohol dose dumping for MR oral drug products containing high risk drugs.

This funding opportunity supports small-scale brain imaging research related to substance use and addiction, aimed at helping both new and established researchers develop innovative studies that enhance our understanding of neurobiological mechanisms in these areas.

This funding opportunity provides financial support to organizations and governments focused on implementing community-based restorative practices to address domestic violence, sexual assault, and stalking, promoting victim safety and accountability outside traditional legal systems.

This funding opportunity supports research teams from various sectors to explore how sex differences influence the biological factors related to Alzheimer’s disease and its treatment, aiming to enhance understanding and improve precision medicine approaches.

This grant provides funding for innovative and high-risk technology development projects in biomedical research that are in the early exploratory stages and have not yet been proven feasible.

This funding opportunity provides financial support for research projects that aim to improve healthcare access and outcomes for individuals with disabilities by addressing the barriers they face in receiving necessary services.

The U.S. Department of Energys (DOE) Office of Energy Efficiency and Renewable Energy (EERE) Building Technologies Office (BTO) is issuing this Funding Opportunity Announcement (FOA) titled Bipartisan Infrastructure Law (BIL): Resilient and Efficient Codes Implementation (RECI). The current FOA represents the second installment in the RECI initiative, which maintains the same broad format, flexibility, and crosscutting areas of interest, while emphasizing and prioritizing specific gaps, needs, and opportunities to support building energy codes identified as focal points through the first RECI FOA and continued stakeholder engagement. The activities to be funded under the FOA support the BIL, as well as a broader government-wide approach to advance building codes and support their successful implementation. The primary focus centers around updating to more efficient building energy codes that save money for American homes and businesses, reduce greenhouse gas (GHG) emissions, and encourage more resilient buildings. This FOA includes one topic area broadly focused on the cost-effective implementation of updated energy codes.

This grant provides funding for innovative and high-risk research projects in biomedical, behavioral, or clinical fields, aimed at early-stage ideas that could lead to significant advancements.

This funding opportunity supports researchers in discovering and validating new targets for developing safe and effective pain treatments with minimal side effects and low addiction risk.

This funding opportunity provides financial support to rural healthcare organizations in the Delta region to improve service delivery, enhance sustainability, and expand access to care through specific projects.

This funding opportunity provides financial support to designated regional consortia that include educational institutions, government entities, and industry partners to advance critical technologies and foster economic growth in their areas.